Rallybio/$RLYB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rallybio
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Ticker
$RLYB
Sector
Primary listing
Employees
14
Headquarters
Website
Rallybio Metrics
BasicAdvanced
$43M
-
-$1.59
-1.13
-
Price and volume
Market cap
$43M
Beta
-1.13
52-week high
$11.49
52-week low
$3.67
Average daily volume
247K
Financial strength
Current ratio
14.505
Quick ratio
12.961
Long term debt to equity
0.141
Total debt to equity
0.304
Profitability
EBITDA (TTM)
-31.272
Gross margin (TTM)
-2,044.17%
Net profit margin (TTM)
-1,046.39%
Operating margin (TTM)
-3,655.48%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-30.07%
Return on equity (TTM)
-15.01%
Valuation
Price to revenue (TTM)
53.932
Price to book
0.75
Price to tangible book (TTM)
0.75
Price to free cash flow (TTM)
-1.552
Free cash flow yield (TTM)
-64.43%
Free cash flow per share (TTM)
-5.296
Growth
Revenue change (TTM)
34.91%
Earnings per share change (TTM)
-84.97%
3-year earnings per share growth (CAGR)
-54.34%
Rallybio News
AllArticlesVideos
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Business Wire·4 weeks ago
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
Benzinga·4 weeks ago
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rallybio stock?
Rallybio (RLYB) has a market cap of $43M as of March 30, 2026.
What is the P/E ratio for Rallybio stock?
The price to earnings (P/E) ratio for Rallybio (RLYB) stock is 0 as of March 30, 2026.
Does Rallybio stock pay dividends?
No, Rallybio (RLYB) stock does not pay dividends to its shareholders as of March 30, 2026.
When is the next Rallybio dividend payment date?
Rallybio (RLYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Rallybio?
Rallybio (RLYB) has a beta rating of -1.13. This means that it has an inverse relation to market volatility.